Results 261 to 270 of about 77,108 (288)

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

Journal of Clinical Oncology, 2022
PURPOSE Limited prospective data are available on sequential immunotherapy and BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma. METHODS SECOMBIT is a randomized, three-arm, noncomparative phase II trial (ClinicalTrials.gov identifier ...
P. Ascierto, M. Mandalà, P. Ferrucci, M. Guidoboni, P. Rutkowski, V. Ferraresi, A. Arance, M. Guida, E. Maiello, H. Gogas, E. Richtig, M. Fierro, C. Lebbé, H. Helgadottir, P. Queirolo, F. Spagnolo, M. Tucci, M. Del Vecchio, Maria Gonzales Cao, A. Minisini, S. De Placido, M. Sanmamed, D. Mallardo, M. Curvietto, I. Melero, G. Palmieri, A. Grimaldi, D. Giannarelli, R. Dummer, V. Chiarion Sileni   +29 more
semanticscholar   +1 more source

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

New England Journal of Medicine
BACKGROUND Phase 1-2 trials involving patients with resectable, macroscopic stage III melanoma have shown that neoadjuvant immunotherapy is more efficacious than adjuvant immunotherapy.
C. U. Blank, M. Lucas, R. Scolyer, B. A. Van de Wiel, A. Menzies, M. Lopez-Yurda, L. Hoeijmakers, Robyn P M Saw, J. Lijnsvelt, Nigel G Maher, Saskia M Pulleman, Maria Gonzalez, A. Torres Acosta, W. V. van Houdt, Serigne N. Lo, Anke M J Kuijpers, A. Spillane, W. Klop, T. Pennington, C. Zuur, K. F. Shannon, Beatrijs A. Seinstra, R. Rawson, J. Haanen, S. Ch’ng, K. Naipal, Jonathan Stretch, J. V. van Thienen, M. Rtshiladze, S. Wilgenhof, R. Kapoor, Aafke Meerveld-Eggink, L. Grijpink-Ongering, A. V. Van Akkooi, I. Reijers, D. Gyorki, D. Grünhagen, F. Speetjens, Sonja B. Vliek, J. Placzke, L. Spain, R. C. Stassen, M. Amini-Adle, C. Lebbé, M. Faries, Caroline Robert, P. Ascierto, R. V. van Rijn, F. van den Berkmortel, D. Piersma, A. Van der Westhuizen, Gerard Vreugdenhil, M. J. Aarts, Marion A. Stevense-den Boer, V. Atkinson, M. Khattak, Miles C Andrews, A. van den Eertwegh, M. Boers-Sonderen, G. Hospers, M. Carlino, J. D. de Groot, E. Kapiteijn, K. Suijkerbuijk, Piotr Rutkowski, S. Sandhu, A. V. D. van der Veldt, Georgina V. Long   +67 more
semanticscholar   +1 more source

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

New England Journal of Medicine
Background The phase 3 CheckMate 067 trial has demonstrated improved survival with nivolumab-plus-ipilimumab or nivolumab monotherapy compared with ipilimumab monotherapy in patients with advanced melanoma. Here, we report the final, 10-year results from
J. Wolchok, V. Chiarion-Sileni, Piotr Rutkowski, C. Cowey, D. Schadendorf, John Wagstaff, Paola Queirolo, R. Dummer, Marcus O. Butler, A. Hill, Michael A. Postow, C. Gaudy-Marqueste, Theresa Medina, Christopher D. Lao, J. Walker, I. Márquez-Rodas, John B. A G. Haanen, M. Guidoboni, Michele Maio, P. Schöffski, M. Carlino, S. Sandhu, Céleste Lebbé, P. Ascierto, Georgina V. Long, C. Ritchings, A. Nassar, M. Askelson, Melanie Pe Benito, Wenjia Wang, F. Hodi, J. Larkin   +31 more
semanticscholar   +1 more source

Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.

New England Journal of Medicine
BACKGROUND Patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer have poor outcomes with standard chemotherapy with or without targeted therapies.
Thierry Andre, E. Élez, Eric Van Cutsem, Lars Henrik Jensen, Jaafar Bennouna, Guillermo Mendez, M. Schenker, C. de la Fouchardière, M. L. Limon, T. Yoshino, Jin Li, H. Lenz, J. L. Manzano Mozo, G. Tortora, R. Garcia-Carbonero, Laetitia Dahan, M. Chalabi, Rohit Joshi, E. Goekkurt, M. Braghiroli, T. Çil, E. Cela, Tian Chen, Ming Lei, Matthew Dixon, S. Abdullaev, S. Lonardi   +26 more
semanticscholar   +1 more source

Ipilimumab

Reactions Weekly, 2018
  +8 more sources

Ipilimumab

Reactions Weekly, 2013
  +7 more sources

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden

Journal for ImmunoTherapy of Cancer
Background Checkpoint inhibitor therapy has demonstrated overall survival benefit in multiple tumor types. Tumor mutational burden (TMB) is a predictive biomarker for response to immunotherapies.
M. Schenker, M. Burotto, M. Richardet, T. Ciuleanu, A. Gonçalves, N. Steeghs, Patrick Schoffski, P. Ascierto, M. Maio, I. Lugowska, L. Lupinacci, A. Leary, J. Delord, Julieta Grasselli, D. Tan, Jennifer Friedmann, J. Vuky, M. Tschaika, Somasekhar Konduru, S. V. Vemula, R. Slepetis, G. Kollia, M. Pacius, Q. Duong, Ning Huang, Parul Doshi, J. Baden, Massimo Di Nicola   +27 more
semanticscholar   +1 more source

Ipilimumab/ipilimumab/nivolumab

Reactions Weekly, 2022
openaire   +1 more source

Ipilimumab

Reactions Weekly, 2017
  +6 more sources

Ipilimumab

Reactions Weekly, 2016
  +6 more sources